Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Immix Biopharma (NASDAQ:IMMX) announced its quarterly earnings data on Monday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.09, Zacks reports.

Immix Biopharma Price Performance

Immix Biopharma stock traded down $0.02 during trading hours on Wednesday, reaching $1.83. The stock had a trading volume of 12,323 shares, compared to its average volume of 133,311. The stock has a market cap of $50.34 million, a PE ratio of -2.15 and a beta of 0.26. The company has a fifty day simple moving average of $1.86 and a 200-day simple moving average of $1.86. Immix Biopharma has a 52 week low of $1.26 and a 52 week high of $3.23.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Immix Biopharma in a research report on Monday, February 10th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.